keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker lymphoma

keyword
https://www.readbyqxmd.com/read/28076864/inflammatory-biomarkers-in-diffuse-large-b-cell-lymphoma-time-for-extending-the-established-prognosis-scores
#1
Florian Posch, Martin Pichler
No abstract text is available yet for this article.
January 12, 2017: Acta Haematologica
https://www.readbyqxmd.com/read/28063905/trichloroethylene-induced-formic-aciduria-in-the-male-c57-bl-6-mouse
#2
Edward A Lock, Paul Keane, Philip H Rowe, John R Foster, Daniel Antoine, Christopher M Morris
1, 1, 2-Trichloroethylene (TCE) is of environmental concern, due to evaporation while handling, chemical processing and leakage from chemical waste sites, leading to its contamination of ground water and air. For several decades there has been issues about possible long term health effects of TCE but recently the International Agency for Research on Cancer (IARC) and the US Environmental Protection Agency classified TCE as a human carcinogen. Links having been established between occupational exposures and kidney cancer and possible links to non-Hodgkin lymphoma and liver cancer, but there is more still more to learn...
January 4, 2017: Toxicology
https://www.readbyqxmd.com/read/28062796/integrated-cellular-and-plasma-proteomics-of-contrasting-b-cell-cancers-reveals-common-unique-and-systemic-signatures
#3
Harvey E Johnston, Matthew J Carter, Kerry L Cox, Melanie Dunscombe, Antigoni Manousopoulou, Paul A Townsend, Spiro D Garbis, Mark S Cragg
Approximately 800,000 leukaemia and lymphoma cases are diagnosed worldwide each year. Burkitt's lymphoma (BL) and chronic lymphocytic leukaemia (CLL), are examples of contrasting B-cell cancers; BL is a highly aggressive lymphoid tumour, frequently affecting children, whilst CLL typically presents as an indolent, slow-progressing leukaemia affecting the elderly. The B-cell-specific over-expression of the myc and tcl1 oncogenes in mice induce spontaneous malignancies modelling BL and CLL, respectively. Quantitative mass spectrometry proteomics and isobaric labelling were employed to examine the biology underpinning contrasting Eμ-myc and Eμ-TCL1 B-cell tumours...
January 4, 2017: Molecular & Cellular Proteomics: MCP
https://www.readbyqxmd.com/read/28061489/the-influence-of-biomarker-mutations-and-systemic-treatment-on-cerebral-metastases-from-nsclc-treated-with-radiosurgery
#4
Min Ho Lee, Doo-Sik Kong, Ho Jun Seol, Do-Hyun Nam, Jung-Il Lee
OBJECTIVE: The purpose of this study was to analyze outcomes and identify prognostic factors in patients with cerebral metastases from non-small cell lung cancer (NSCLC) treated with gamma knife radiosurgery (GKS) particularly, focusing on associations of biomarkers and systemic treatments. METHODS: We retrospectively reviewed the medical records of 134 patients who underwent GKS for brain metastases due to NSCLC between January 2002 and December 2012. Representative biomarkers including epidermal growth factor receptor (EGFR) mutation, K-ras mutation, and anaplastic lymphoma kinase (ALK) mutation status were investigated...
January 1, 2017: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/28060891/performance-of-89zr-labeled-rituximab-pet-as-an-imaging-biomarker-to-assess-cd20-targeting-a-pilot-study-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma
#5
Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman
PURPOSE: Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging biomarker for tumor targeting, since it depends on target antigen expression and accessibility. The aim of this pilot study was to describe the performance of 89Zr-labeled-rituximab-PET to assess CD20 targeting in patients with relapsed/refractory DLBCL...
2017: PloS One
https://www.readbyqxmd.com/read/28060738/the-prognostic-value-of-clonal-heterogeneity-and-quantitative-assessment-of-plasma-circulating-clonal-ig-vdj-sequences-at-diagnosis-in-patients-with-follicular-lymphoma
#6
Clémentine Sarkozy, Sarah Huet, Victoria E H Carlton, Bettina Fabiani, Alain Delmer, Fabrice Jardin, Marie-Helene Delfau-Larue, Maya Hacini, Vincent Ribrag, Stéphanie Guidez, Malek Faham, Gilles Salles
Recent advances in next-generation sequencing (NGS) have enabled the quantitation of circulating tumour DNA (ctDNA) encoding the clonal rearranged V(D)J immunoglobulin locus. We aimed to evaluate the clonal heterogeneity of follicular lymphoma (FL) in the tumour and the plasma at diagnosis and to assess the prognostic value of the ctDNA level. Plasma samples at diagnosis were available for 34 patients registered in the PRIMA trial (NCT00140582). One tumour clonotype or more could be detected for 29 (85%) and 25 (74%) patients, respectively, in the tumour or plasma samples...
January 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28056299/-application-of-rabbit-monoclonal-antibody-gcet2-in-diagnosis-of-diffuse-large-b-cell-lymphoma
#7
H Y Pan, X X Zhang, Y Y Weng, R Zhou
Objective: To prepare a rabbit monoclonal antibody GCET2 and to investigate its diagnostic value in the workup of diffuse large B-cell lymphoma (DLBCL). Methods: GCET2 rabbit monoclonal antibody was developed by using RabMAb(®) technology, and its specificity was confirmed by ELISA, Western blot, immunohistochemistry (IHC) and flow cytometry. A panel of immunomarkers including GCET2, CD10, bcl-6, MUM1, GCET1, FOXP1, Ki-67 and CMYC was evaluated in 81 cases of DLBCLs, 5 cases of follicular lymphomas (FL) and 2 cases of Burkitt's lymphomas...
December 8, 2016: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28040700/hodgkin-lymphoma-current-status-and-clinical-trial-recommendations
#8
REVIEW
Catherine S Diefenbach, Joseph M Connors, Jonathan W Friedberg, John P Leonard, Brad S Kahl, Richard F Little, Lawrence Baizer, Andrew M Evens, Richard T Hoppe, Kara M Kelly, Daniel O Persky, Anas Younes, Lale Kostakaglu, Nancy L Bartlett
The National Clinical Trials Network lymphoid malignancies Clinical Trials Planning Meeting (CTPM) occurred in November of 2014. The scope of the CTPM was to prioritize across the lymphoid tumors clinically significant questions and to foster strategies leading to biologically informed and potentially practice changing clinical trials. This review from the Hodgkin lymphoma (HL) subcommittee of the CTPM discusses the ongoing clinical challenges in HL, outlines the current standard of care for HL patients from early to advanced stage, and surveys the current science with respect to biomarkers and the landscape of ongoing clinical trials...
April 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28040699/recommendations-for-clinical-trial-development-in-follicular-lymphoma
#9
REVIEW
Kami Maddocks, Paul M Barr, Bruce D Cheson, Richard F Little, Lawrence Baizer, Brad S Kahl, John P Leonard, Nathan Fowler, Leo I Gordon, Brian K Link, Jonathan W Friedberg, Stephen M Ansell
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies...
March 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28040682/t-cell-lymphoma-recent-advances-in-characterization-and-new-opportunities-for-treatment
#10
REVIEW
Carla Casulo, Owen O'Connor, Andrei Shustov, Michelle Fanale, Jonathan W Friedberg, John P Leonard, Brad S Kahl, Richard F Little, Lauren Pinter-Brown, Ranjani Advani, Steven Horwitz
Peripheral T-cell lymphomas (PTCLs) are uncommon, heterogeneous, and aggressive non-Hodgkin's lymphomas. Despite progress in the last several years resulting in a deeper understanding of PTCL biology and pathogenesis, there is currently no accepted single standard of care for newly diagnosed patients, and for those with relapsed or refractory disease, prognosis is dismal. The National Cancer Institute convened a Clinical Trials Planning Meeting to advance the national clinical trial agenda in lymphoma. The objective was to identify unmet needs specific to five major lymphoma subtypes and develop strategies to address them...
February 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28036275/lymphocyte-to-monocyte-ratio-is-associated-with-prognosis-of-diffuse-large-b-cell-lymphoma-correlation-with-cd163-positive-m2-type-tumor-associated-macrophages-not-pd-1-positive-tumor-infiltrating-lymphocytes
#11
Jingxuan Wang, Kun Gao, Wanting Lei, Lina Dong, Qijia Xuan, Meiyan Feng, Jinlu Wang, Xiangnan Ye, Tuan Jin, Zhongbai Zhang, Qingyuan Zhang
The research aims to examine the prognostic value of the lymphocyte-to-monocyte ratio (LMR), neutrophil-to- lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in diffuse large B-cell lymphoma (DLBCL). The relation of these hematologic indicators to poor antitumor immunity and prognosis must be investigated. Clinicopathologic data and survival information of 355 patients with DLBCL was retrospectively analyzed. Univariate analysis revealed that lower LMR (<2.71), higher NLR (≥2.81), CD163+ M2 tumor-associated macrophages (TAM) content ≥9...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/28035137/soluble-programmed-death-ligand-1-as-a-prognostic-biomarker-for-overall-survival-in-patients-with-diffuse-large-b-cell-lymphoma-a-replication-study-and-combined-analysis-of-508-patients
#12
D Rossille, I Azzaoui, A L Feldman, M J Maurer, G Labouré, M Parrens, C Pangault, T M Habermann, S M Ansell, B K Link, K Tarte, T E Witzig, T Lamy, S L Slager, M Roussel, N Milpied, J R Cerhan, T Fest
Leukemia accepted article preview online, 30 December 2016. doi:10.1038/leu.2016.385.
December 30, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28032275/cd109-a-negative-regulator-of-tgf-%C3%AE-signaling-is-a-putative-risk-marker-in-diffuse-large-b-cell-lymphoma
#13
Maki Yokoyama, Masaaki Ichinoe, Sosei Okina, Yasutaka Sakurai, Norihiro Nakada, Nobuyuki Yanagisawa, Shi-Xu Jiang, Yoshiko Numata, Atsuko Umezawa, Koji Miyazaki, Masaaki Higashihara, Yoshiki Murakumo
CD109 is a glycosylphosphatidylinositol-anchored glycoprotein that negatively regulates TGF-β signaling. CD109 was originally identified in hematopoietic tumors; however, the significance of CD109 in hematopoietic malignancies remains unclear. Here, we study the association of CD109 with diffuse large B-cell lymphoma (DLBCL) prognosis. Eighty-four DLBCL specimens were immunohistochemically analyzed for CD109 expression, and 31 and 53 cases were classified into low- and high-CD109 expression groups, respectively...
December 28, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/28031239/micrornas-142-3p-mir-155-and-mir-203-are-deregulated-in-gastric-malt-lymphomas-compared-to-chronic-gastritis
#14
Concepción Fernández, Beatriz Bellosillo, Mariana Ferraro, Agustín Seoane, Blanca Sánchez-González, Silvia Pairet, Aina Pons, Luis Barranco, María Carmen Vela, Eva Gimeno, Lluís Colomo, Carles Besses, Alfons Navarro, Antonio Salar
BACKGROUND: Over the last years, our knowledge on pathogenesis of gastric MALT lymphoma has greatly improved, but its morphological diagnosis is still hampered by overlapping histological features with advanced chronic gastritis. MicroRNAs are deregulated in lymphomas, but their role and usefulness in gastric MALT lymphoma has not been extensively investigated. MATERIALS AND METHODS: We analyzed the expression of 384 miRNAs using TaqMan microRNA assay in a training series of 10 gastric MALT lymphomas, 3 chronic gastritis and 2 reactive lymph nodes...
January 2017: Cancer Genomics & Proteomics
https://www.readbyqxmd.com/read/27999330/dysregulated-microrna-expression-profiles-and-potential-cellular-circulating-and-polymorphic-biomarkers-in-non-hodgkin-lymphoma
#15
REVIEW
Gabrielle Bradshaw, Heidi G Sutherland, Larisa M Haupt, Lyn R Griffiths
A large number of studies have focused on identifying molecular biomarkers, including microRNAs (miRNAs) to aid in the diagnosis and prognosis of the most common subtypes of non-Hodgkin lymphoma (NHL), Diffuse Large B-cell Lymphoma and Follicular Lymphoma. NHL is difficult to diagnose and treat with many cases becoming resistant to chemotherapy, hence the need to identify improved biomarkers to aid in both diagnosis and treatment modalities. This review summarises more recent research on the dysregulated miRNA expression profiles found in NHL, as well as the regulatory role and biomarker potential of cellular and circulating miRNAs found in tissue and serum, respectively...
December 17, 2016: Genes
https://www.readbyqxmd.com/read/27998273/lncrna-malat1-promotes-development-of-mantle-cell-lymphoma-by-associating-with-ezh2
#16
Xin Wang, Lalit Sehgal, Neeraj Jain, Tamer Khashab, Rohit Mathur, Felipe Samaniego
BACKGROUND: Mantle cell lymphoma (MCL) is considered an aggressive subtype of non-Hodgkin's lymphoma with variable treatment responses. There is an urgent need to identify novel markers with prognostic and therapeutic value for MCL. Long non-coding RNAs (lncRNAs) have emerged as key regulators in cancers, including MCL. Metastasis-associated lung adenocarcinoma transcript 1(MALAT1), a lncRNA located at pathognomonic translocation site of t (11; 14) of MCL. MALAT1 is known to be overexpressed in solid tumors and hematologic malignancies...
December 20, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27997139/isotope-dilution-nanolc-esi-hrms-3-quantitation-of-urinary-n7-1-hydroxy-3-buten-2-yl-guanine-adducts-in-humans-and-their-use-as-biomarkers-of-exposure-to-1-3-butadiene
#17
Dewakar Sangaraju, Emily J Boldry, Yesha M Patel, Vernon Walker, Irina Stepanov, Daniel O Stram, Dorothy K Hatsukami, Natalia Y Tretyakova
1,3-Butadiene (BD) is an important industrial and environmental chemical classified as a known human carcinogen. Occupational exposure to BD in the polymer and monomer industries is associated with an increased incidence of lymphoma. BD is present in automobile exhaust, cigarette smoke, and forest fires, raising concern about potential exposure of general population to this carcinogen. Following inhalation exposure, BD is bioactivated to 3,4-epoxy-1-butene (EB). If not detoxified, EB is capable of modifying guanine and adenine bases of DNA to form nucleobase adducts, which interfere with accurate DNA replication and cause cancer-initiating mutations...
December 20, 2016: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/27991481/circulating-microrna-21-microrna-23a-and-microrna-125b-as-biomarkers-for-diagnosis-and-prognosis-of-burkitt-lymphoma-in-children
#18
Jun Li, Xiao-Wen Zhai, Hong-Sheng Wang, Xiao-Wen Qian, Hui Miao, Xiao-Hua Zhu
BACKGROUND The aim of this study was to investigate the diagnostic and prognostic value of microRNA (miRNA)-21, miRNA-23a, and miRNA-125b in Burkitt lymphoma (BL) in children. MATERIAL AND METHODS We recruited 41 children with BL for the case group, 56 children with lymph node inflammation for the positive control group, and 60 healthy children for the negative control group. Real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) was conducted for detection of circulating miRNA-21, miRNA-23a, and miRNA-125b...
December 19, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/27986884/beyond-rchop-a-blueprint-for-diffuse-large-b-cell-lymphoma-research
#19
REVIEW
Grzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, Jonathan W Friedberg, Lawrence Baizer, Richard F Little, David G Maloney, Laurie H Sehn, Michael E Williams, Wyndham H Wilson, John P Leonard, Sonali M Smith
Diffuse large B cell lymphoma (DLBCL) comprises multiple molecular and biological subtypes, resulting in a broad range of clinical outcomes. With standard chemoimmunotherapy, there remains an unacceptably high treatment failure rate in certain DLBCL subsets: activated B cell (ABC) DLBCL, double-hit lymphoma defined by the dual translocation of MYC and BCL2, dual protein-expressing lymphomas defined by the overexpression of MYC and BCL2, and older patients and those with central nervous system involvement. The main research challenges for DLBCL are to accurately identify molecular subsets and to determine if specific chemotherapy platforms and targeted agents offer differential benefit...
December 2016: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/27986882/general-biomarker-recommendations-for-lymphoma
#20
Lisa Rimsza, Yuri Fedoriw, Louis M Staudt, Ari Melnick, Randy Gascoyne, Michael Crump, Lawrence Baizer, Kai Fu, Eric Hsi, John W C Chan, Lisa McShane, John P Leonard, Brad S Kahl, Richard F Little, Jonathan W Friedberg, Lale Kostakoglu
Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways...
December 2016: Journal of the National Cancer Institute
keyword
keyword
7294
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"